RIBOMIC Inc.【JP:4591】Other
Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Return on Assets | - | - | - | - | -0.2 | -6.9 | -9.7 | -6.2 | -8.4 | -8 | -10.3 | -3.7 | -5.4 | -8.3 |
| Return on equity (%) | - | - | - | |||||||||||
| Employees | 18 | 17 | 16 | 18 | 20 | 20 | 21 | 21 | 22 | 25 | 26 | 25 | 24 | 25 |